ArticleDiscover oncology2025
Global research landscape on active surveillance for papillary thyroid microcarcinoma: a bibliometric analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic Factors and Recurrence in Papillary Thyroid Microcarcinoma.Medicina (Kaunas, Lithuania) · 2026Article
- Active surveillance or surgical resection? A survey of treatment strategies for low-risk papillary thyroid microcarcinoma in adults.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt has been proven that the active surveillance (AS) is safe and feasible for low-risk papillary thyroid microcarcinomas (PTMC). There has been no bibliometric assessment of the scientific advancements in this field. We conducted this study to determine the characteristics and trends of published research on AS for PTMC.
methodsIn this study, articles on AS for PTMC published between 2014 and 2024 were identified using the Web of Science Core Collection database. Bibliometric analysis and visualization were conducted using VOSviewer and CiteSpace.
results277 publications from 39 countries were identified, demonstrating a growth trend between 2014 and 2024. The United States of America dominated with the highest number of published papers, followed closely by South Korea and Japan. The most significant journal was *Thyroid*, and the leading author was Akira Miyauchi. Kuma Hospital and Memorial Sloan Kettering Cancer Center emerged as leading institutions. Keyword analysis revealed that, alongside the title-related terms of this study, "management," "quality of life," "lymph node metastasis," "progression," and "association guidelines" formed the core keywords in this field.
conclusionActive surveillance for low-risk PTMC has been endorsed and recommended by researchers in numerous countries. This study identified the current most active frontiers in this field and focused on candidate population profiling, tumor progression evaluation, cost-effectiveness of the active surveillance (AS) approach, and quality of life assessment for patients. This paper summarizes the controversial issues and provides a reference direction for researchers seeking to explore novel approaches in this field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.